Compare FMY & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMY | NSRX |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 53.5M |
| IPO Year | N/A | N/A |
| Metric | FMY | NSRX |
|---|---|---|
| Price | $12.12 | $5.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 3.6K | 1.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.65 | $4.90 |
| 52 Week High | $12.39 | $9.99 |
| Indicator | FMY | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 36.93 |
| Support Level | $12.06 | $4.90 |
| Resistance Level | $12.18 | $6.47 |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 66.67 | 9.55 |
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.